Cargando…
Complete response in patients with locally advanced rectal cancer after neoadjuvant treatment with nivolumab
Introduction: PD-1 inhibitors have been approved for the treatment of dMMR patients with metastatic colorectal cancer, but the efficacy of neoadjuvant treatment with PD-1 in dMMR locally advanced rectal cancer (LARC) patients has not yet been defined. Patients and methods: Two patients with LARC rec...
Autores principales: | Zhang, Jianwei, Cai, Jian, Deng, Yanhong, Wang, Hui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6844302/ https://www.ncbi.nlm.nih.gov/pubmed/31741760 http://dx.doi.org/10.1080/2162402X.2019.1663108 |
Ejemplares similares
-
Complete Pathological Response After Neoadjuvant Short‐Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI‐H/dMMR Rectal Cancer
por: Trojan, Jörg, et al.
Publicado: (2021) -
Reduction of circulating lymphocyte count is a predictor of good tumor response after neoadjuvant treatment for rectal cancer
por: Wu, Zehua, et al.
Publicado: (2018) -
The prognostic and predictive value of mismatch repair status in patients with locally advanced rectal cancer following neoadjuvant therapy
por: Wu, Zehua, et al.
Publicado: (2022) -
Advances for achieving a pathological complete response for rectal cancer after neoadjuvant therapy
por: Cui, Jian, et al.
Publicado: (2016) -
Nomogram basing pre-treatment parameters predicting early response for locally advanced rectal cancer with neoadjuvant chemotherapy alone: a subgroup efficacy analysis of FOWARC study
por: Zhang, Jianwei, et al.
Publicado: (2015)